Related references
Note: Only part of the references are listed.Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: A study by the National Cancer Institute Organ Dysfunction Working Group
Joseph Gibbons et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: A study by the National Cancer Institute Organ Dysfunction Working Group
Ramesh K. Ramanathan et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT
Charles D. Blanke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia
L. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels
N. Widmer et al.
LEUKEMIA (2007)
Imatinib disposition and ABCB1 (MDR1, p-glycoprotein) genotype
H. Gurney et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Reducing uncertainty in health-care resource allocation
T. Simonsson et al.
BRITISH JOURNAL OF CANCER (2007)
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
Stephane Picard et al.
BLOOD (2007)
Reply: The long-term response to imatinib treatment of CML
F. Michor
BRITISH JOURNAL OF CANCER (2007)
Therapeutic drug monitoring in CML patients on imatinib
Carolyn Blasdel et al.
BLOOD (2007)
Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure
Feng R. Luo et al.
CLINICAL CANCER RESEARCH (2006)
Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors
Catherine Delbaldo et al.
CLINICAL CANCER RESEARCH (2006)
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Risto Kerkela et al.
NATURE MEDICINE (2006)
Population pharmacokinetics of imatinib and the role of α1-acid glycoprotein
N. Widmer et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
Maria Debiec-Rychter et al.
EUROPEAN JOURNAL OF CANCER (2006)
Side effects during chemotherapy predict tumour response in advanced colorectal cancer
B Schuell et al.
BRITISH JOURNAL OF CANCER (2005)
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg
JR Zalcberg et al.
EUROPEAN JOURNAL OF CANCER (2005)
Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study
H Schmidli et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Dynamics of chronic myeloid leukaemia
F Michor et al.
NATURE (2005)
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation
CR Antonescu et al.
CLINICAL CANCER RESEARCH (2005)
Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group
I Judson et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia
E Gambillara et al.
DERMATOLOGY (2005)
Imatinib mesylate in the treatment of gastrointestinal stromal tumour
DM Steinert et al.
EXPERT OPINION ON PHARMACOTHERAPY (2005)
Determination of imatinib (Gleevec®) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection
N Widmer et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2004)
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients
B Peng et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group
M Debiec-Rychter et al.
EUROPEAN JOURNAL OF CANCER (2004)
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
J Verweij et al.
LANCET (2004)
Imatinib therapy in chronic myelogenous leukemia:: strategies to avoid and overcome resistance
A Hochhaus et al.
LEUKEMIA (2004)
Active transport of imatinib into and out of cells: implications for drug resistance
J Thomas et al.
BLOOD (2004)
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
MC Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec®) in vitro and in vivo
J Larghero et al.
BIOCHEMICAL PHARMACOLOGY (2003)
Resistance to imatinib (Glivec): update on clinical mechanisms
E Weisberg et al.
DRUG RESISTANCE UPDATES (2003)
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models
FX Mahon et al.
BLOOD (2003)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug
R Capdeville et al.
NATURE REVIEWS DRUG DISCOVERY (2002)
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
CL Sawyers et al.
BLOOD (2002)
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
M Talpaz et al.
BLOOD (2002)
Cutaneous reactions to STI571
M Brouard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Role of α1 acid glycoprotein in the in vivo resistance of human BCR-ABL+ leukemic cells to the Abl inhibitor STI571
C Gambacorti-Passerini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
